| Literature DB >> 28469520 |
Murat Özcan1, S Ümit Sarici1, Yüksel Yurdugül1, Melis Akpinar1, Demet Altun1, Begüm Özcan2, Muhittin A Serdar3, Dilek Sarici4.
Abstract
BACKGROUND ANDEntities:
Keywords: Newborn; early jaundice; significant hyperbilirubinemia; urinary tract infection
Year: 2017 PMID: 28469520 PMCID: PMC5398657 DOI: 10.1177/1179556517701118
Source DB: PubMed Journal: Clin Med Insights Pediatr ISSN: 1179-5565
Demographic and laboratory characteristics of newborns with significant hyperbilirubinemia and diagnosed to have urinary tract infection (n = 26).
| Case | Age ON admission, h | Birth weight, g | Sex | Growing microorganism on urine culture and its amount, CFU/mL | SERUM TOTAL BILIRUBIN, MG/DL[ | Abnormality on renal ultrasonography |
|---|---|---|---|---|---|---|
| 2 | 126 | 2910 | Male | 100 000 | 19.9 | Normal |
| 6 | 162 | 2110 | Male | 50 000 | 15.2 | Normal |
| 7 | 120 | 3260 | Female | 10 000 | 23.9 | Normal |
| 8 | 78 | 3260 | Male | 100 000 | 17.4 | Normal |
| 10 | 79 | 3450 | Male | 10 000 | 24.1 | Normal |
| 11 | 236 | 2500 | Male | 100 000 | 18 | Normal |
| 12 | 122 | 3150 | Male | 20 000 | 20 | Normal |
| 14 | 48 | 3770 | Male | 100 000 | 17.9 | Normal |
| 15 | 96 | 3370 | Male | 50 000 | 19.6 | Normal |
| 16 | 152 | 3850 | Male | 50 000 | 19.9 | Normal |
| 17 | 107 | 4000 | Male | 100 000 | 21.4 | Normal |
| 18 | 54 | 3700 | Female | 30 000 | 13.4 | Normal |
| 19 | 162 | 4160 | Male | 30 000 | 24.9 | Normal |
| 20 | 216 | 2000 | Male | 100 000 | 20.6 | Normal |
| 22 | 76 | 3200 | Male | 100 000 | 20.2 | Normal |
| 23 | 176 | 3600 | Male | 100 000 | 17.3 | Normal |
| 24 | 98 | 3200 | Male | 50 000 | 23 | Normal |
| 25 | 66 | 3530 | Male | 100 000 | 16.1 | Normal |
| 26 | 144 | 3150 | Male | 100 000 | 19.5 | Normal |
| 1 | 239 | 2830 | Female | 30 000 | 20.7 | Left pelviectasis |
| 3 | 99 | 3680 | Male | 100 000 | 18.4 | Unilateral cortical cyst |
| 4 | 168 | 3240 | Male | 100 000 | 24.7 | Left pelviectasis |
| 5 | 121 | 4170 | Male | 100 000 | 20.6 | Minimal dilatation in bilateral renal pelvises |
| 9 | 96 | 3060 | Male | 100 000 | 23.3 | Left hydronephrosis |
| 13 | 119 | 3900 | Male | 30 000 | 23.7 | Bilateral pelviectasis |
| 21 | 40 | 3690 | Male | 100 000 | 18.4 | Right renal solid cyst |
1 mg/dL bilirubin = 17.1 µmol/L bilirubin.
Detailed clinical signs and symptoms, laboratory abnormalities, and treatment modalities of newborns with both significant hyperbilirubinemia and urinary tract infection (n = 26).
| Case | Complaints (of the parents) and positive clinical signs and symptoms | Positive laboratory abnormalities | Repeat (control) culture (urine/blood)[ | Treatment |
|---|---|---|---|---|
| 1 | Fever, jaundice | Blood culture + pyuria (46 white blood cell per HPF), high serum bilirubin level (20.7 mg/dL) | Sterile | Teicoplanin IV |
| 2 | Feeding intolerance, jaundice | High BUN/Cre (50 mg/dL/0.7 mg/dL), high serum bilirubin level (19.9 mg/dL) | Sterile | Cefotaxime IV + FR |
| 3 | Jaundice | High serum bilirubin level (18.4 mg/dL) | Sterile | Cefotaxime IV |
| 4 | Jaundice | Pyuria (22 white blood cell per HPF), high serum bilirubin level (24.7 mg/dL) | Sterile | Teicoplanin IV |
| 5 | Jaundice | High serum bilirubin level (20.6 mg/dL) | Sterile | Cefotaxime IV |
| 6 | Feeding intolerance, jaundice | High serum bilirubin level (15.2 mg/dL) | Sterile | Cefotaxime IV |
| 7 | Jaundice | High serum bilirubin level (23.9 mg/dL) | Sterile | Teicoplanin IV |
| 8 | Fever, jaundice | High CRP level (24.1 mg/dL), high | Sterile | Teicoplanin IV |
| 9 | Jaundice | High serum bilirubin level (23.3 mg/dL) | Sterile | Teicoplanin IV |
| 10 | Poor weight gain, jaundice | High BUN/Cre (60 mg/dL/0.8 mg/dL), high serum bilirubin level (24.1 mg/dL) | Sterile | Cefotaxime IV + FR |
| 11 | Jaundice | High serum bilirubin level (18 mg/dL) | Sterile | Teicoplanin IV |
| 12 | Jaundice | High serum bilirubin level (20 mg/dL) | Sterile | Teicoplanin IV |
| 13 | Lethargy + irritability, jaundice | High serum bilirubin level (23.7 mg/dL) | Sterile | Teicoplanin IV |
| 14 | Jaundice | High serum bilirubin level (17.9 mg/dL) | Sterile | Cefotaxime IV |
| 15 | Jaundice | High serum bilirubin level (19.6 mg/dL) | Sterile | Teicoplanin IV |
| 16 | Diarrhea, jaundice | High serum bilirubin level (19.9 mg/dL) | Sterile | Cefotaxime IV |
| 17 | Jaundice | High serum bilirubin level (21.4 mg/dL) | Sterile | Cefotaxime IV |
| 18 | Poor tissue perfusion, jaundice | Metabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL) | Sterile | Teicoplanin IV + FR |
| 19 | Jaundice | High serum bilirubin level (24.9 mg/dL) | Sterile | Teicoplanin IV |
| 20 | Jaundice | High serum bilirubin level (20.6 mg/dL) | Sterile | Cefotaxime IV |
| 21 | Jaundice | High serum bilirubin level (18.4 mg/dL) | Sterile | Cefotaxime IV |
| 22 | Fever, jaundice | High CRP level/leukocytosis (44.1 mg/dL/17 800/mm3), high serum bilirubin level (20.2 mg/dL) | Sterile | Teicoplanin IV |
| 23 | Jaundice | High serum bilirubin level (17.3 mg/dL) | Sterile | Cefotaxime IV |
| 24 | Jaundice | High serum bilirubin level (23 mg/dL) | Sterile | Cefotaxime IV |
| 25 | Jaundice | Pyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL) | Sterile | Teicoplanin IV |
| 26 | Jaundice | High serum bilirubin level (19.5 mg/dL) | Sterile | Teicoplanin IV |
Abbreviations: BUN, blood urea nitrogen; Cre, creatinine; CRP, C-reactive protein; FR, fluid replacement; HPF, high-power field; I/T, immature-to-total neutrophils; IV, intravenously.
Cerebrospinal fluid cultures were not required after evaluating the newborn’s general condition and other laboratory test results. Repeat (control) urine and blood cultures were obtained after completion of treatment.
Comparison of demographic and laboratory characteristics of newborns with significant hyperbilirubinemia but without urinary tract infection (group I) and of newborns with both significant hyperbilirubinemia and urinary tract infection (group II).
| Parameter | Group I (n = 129) | Group II (n = 26) | |
|---|---|---|---|
| Gestational age, wk[ | 37.87 ± 1.56 | 37.85 ± 1.19 | .946 |
| Maternal age, y[ | 28.28 ± 5.0 | 29.92 ± 3.82 | .065 |
| Age on admission, h[ | 128.48 ± 75.58 | 127.73 ± 66.63 | .963 |
| Birth weight, g[ | 3131.47 ± 475.63 | 3336.15 ± 555.38 | .054 |
| Weight on admission, g[ | 2987 ± 458.1 | 3175.38 ± 494.14 | .061 |
| Weight loss on admission as percent (if present)[ | 5.08 ± 3.64 | 6.08 ± 5.26 | .242 |
| Serum total bilirubin, mg/dL[ | 18.25 ± 2.94 | 20.08 ± 2.99 | .005 |
| Serum direct bilirubin, mg/dL[ | 0.54 ± 0.13 | 0.69 ± 0.22 | .001 |
| Ratio of direct to total bilirubin levels[ | 0.02992 ± 0.00702 | 0.035188 ± 0.01581 | .0024 |
| Serum total bilirubin at the 24th hour of phototherapy, mg/dL[ | 8.83 ± 1.49 | 10.08 ± 1.42 | .0001 |
| Decrease in serum total bilirubin at 24th hour as percent | 51.55 ± 4.01 | 49.61 ± 3.43 | .022 |
| Hemoglobin, g/dL[ | 17.54 ± 2.17 | 17.3 ± 2.3 | .608 |
| Hematocrit[ | 50.8 ± 6.56 | 50.1 ± 6.67 | .594 |
| Free T4, ng/dL[ | 1.8 ± 2.74 | 1.4 ± 0.2 | .479 |
| TSH, µIU/mL[ | 3.75 ± 1.8 | 3.68 ± 2.12 | .868 |
| Presence of pyuria (present/absent) | 7/122 | 3/23 | .223 |
| Route of delivery (vaginal/cesarean) | 52/78 | 10/16 | .919 |
| Sex (female/male) | 69/60 | 3/23 | .000 |
| Enclosed hemorrhage (present/absent) | 5/124 | 2/24 | .33 |
| Abnormal weight loss (present/absent) | 7/122 | 2/24 | .647 |
| Feeding pattern | |||
| Breast milk (%) | 118 (91.47) | 22 (84.61) | |
| Formula milk (%) | 4 (3.1) | 1 (3.84) | .094 |
| Partially breast milk (%) | 7 (5.42) | 3 (11.53) | |
Values are given as mean ± SD.
1 mg/dL bilirubin = 17.1 µmol/L bilirubin.
Figure 1.Comparison of serum total bilirubin levels in the study groups.
Figure 2.Comparison of percentage decreases in serum total bilirubin levels at the 24th hour of phototherapy in the study groups.